These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 11337546)

  • 1. Impact of 18F-FDG PET on managing patients with colorectal cancer: the referring physician's perspective.
    Meta J; Seltzer M; Schiepers C; Silverman DH; Ariannejad M; Gambhir SS; Phelps ME; Valk P; Czernin J
    J Nucl Med; 2001 Apr; 42(4):586-90. PubMed ID: 11337546
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of whole-body 18F-FDG PET on staging and managing patients with breast cancer: the referring physician's perspective.
    Yap CS; Seltzer MA; Schiepers C; Gambhir SS; Rao J; Phelps ME; Valk PE; Czernin J
    J Nucl Med; 2001 Sep; 42(9):1334-7. PubMed ID: 11535721
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The impact of PET on the management of lung cancer: the referring physician's perspective.
    Seltzer MA; Yap CS; Silverman DH; Meta J; Schiepers C; Phelps ME; Gambhir SS; Rao J; Valk PE; Czernin J
    J Nucl Med; 2002 Jun; 43(6):752-6. PubMed ID: 12050318
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of whole-body (18)F-FDG PET imaging on clinical staging and management of patients with malignant lymphoma.
    Schöder H; Meta J; Yap C; Ariannejad M; Rao J; Phelps ME; Valk PE; Sayre J; Czernin J
    J Nucl Med; 2001 Aug; 42(8):1139-43. PubMed ID: 11483671
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Impact of [18F]-FDG-PET on medical decision making in oncology: evaluation by the referring physicians during the opening year].
    Talbot JN; Rain JD; Meignan M; Askienazy S; Grall Y; Bok B; Misset JL
    Bull Cancer; 2002 Mar; 89(3):313-21. PubMed ID: 11940470
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The clinical impact of (18)F-FDG PET in patients with suspected or confirmed recurrence of colorectal cancer: a prospective study.
    Kalff V; Hicks RJ; Ware RE; Hogg A; Binns D; McKenzie AF
    J Nucl Med; 2002 Apr; 43(4):492-9. PubMed ID: 11937593
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patients with known or suspected lung cancer: evaluation of clinical management changes due to 18F-fluorodeoxyglucose positron emission tomography (18F-FDG PET) study.
    Pepe G; Rossetti C; Sironi S; Landoni C; Gianolli L; Pastorino U; Zannini P; Mezzetti M; Grimaldi A; Galli L; Messa C; Fazio F
    Nucl Med Commun; 2005 Sep; 26(9):831-7. PubMed ID: 16096588
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of 3,4-dihydroxy-6-18F-fluoro-L-phenylalanine PET/CT on managing patients with brain tumors: the referring physician's perspective.
    Walter F; Cloughesy T; Walter MA; Lai A; Nghiemphu P; Wagle N; Fueger B; Satyamurthy N; Phelps ME; Czernin J
    J Nucl Med; 2012 Mar; 53(3):393-8. PubMed ID: 22323780
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The impact of FDG-PET on the management algorithm for recurrent colorectal cancer.
    Arulampalam T; Costa D; Visvikis D; Boulos P; Taylor I; Ell P
    Eur J Nucl Med; 2001 Dec; 28(12):1758-65. PubMed ID: 11734912
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of whole-body 18F-FDG PET on staging and managing patients for radiation therapy.
    Dizendorf EV; Baumert BG; von Schulthess GK; Lütolf UM; Steinert HC
    J Nucl Med; 2003 Jan; 44(1):24-9. PubMed ID: 12515872
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FDG-PET for the pre-operative evaluation of colorectal liver metastases.
    Arulampalam TH; Francis DL; Visvikis D; Taylor I; Ell PJ
    Eur J Surg Oncol; 2004 Apr; 30(3):286-91. PubMed ID: 15028310
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The impact of 2-deoxy-2[18F] fluoro-D-glucose whole body positron emission tomography for managing patients with melanoma: the referring physician's perspective.
    Wong C; Silverman DH; Seltzer M; Schiepers C; Ariannejad M; Gambhir SS; Phelps ME; Rao J; Valk P; Czernin J
    Mol Imaging Biol; 2002 Mar; 4(2):185-90. PubMed ID: 14537142
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical impact of 18F-FDG-PET in the suspicion of recurrent colorectal cancer based on asymptomatically elevated serum level of carcinoembryonic antigen (CEA) in Taiwan.
    Shen YY; Liang JA; Chen YK; Tsai CY; Kao CH
    Hepatogastroenterology; 2006; 53(69):348-50. PubMed ID: 16795969
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Positron emission tomography scanning is not superior to whole body multidetector helical computed tomography in the preoperative staging of colorectal cancer.
    Furukawa H; Ikuma H; Seki A; Yokoe K; Yuen S; Aramaki T; Yamagushi S
    Gut; 2006 Jul; 55(7):1007-11. PubMed ID: 16361308
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Whole-body (18)F-FDG PET improves the management of patients with small cell lung cancer.
    Kamel EM; Zwahlen D; Wyss MT; Stumpe KD; von Schulthess GK; Steinert HC
    J Nucl Med; 2003 Dec; 44(12):1911-7. PubMed ID: 14660716
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Current status of nuclear medicine. Clinical application of FDG-PET for cancer diagnosis. Colorectal cancer].
    Ito K; Kato T
    Nihon Igaku Hoshasen Gakkai Zasshi; 2002 May; 62(6):270-7. PubMed ID: 12073633
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of 68Ga-DOTATATE PET/CT on the management of neuroendocrine tumors: the referring physician's perspective.
    Herrmann K; Czernin J; Wolin EM; Gupta P; Barrio M; Gutierrez A; Schiepers C; Mosessian S; Phelps ME; Allen-Auerbach MS
    J Nucl Med; 2015 Jan; 56(1):70-5. PubMed ID: 25500825
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Routine (18)F-FDG PET preoperative staging of colorectal cancer: comparison with conventional staging and its impact on treatment decision making.
    Kantorová I; Lipská L; Bêlohlávek O; Visokai V; Trubaĉ M; Schneiderová M
    J Nucl Med; 2003 Nov; 44(11):1784-8. PubMed ID: 14602860
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early clinical experience and impact of 18F-FDG PET.
    Gutte H; Højgaard L; Kjaer A
    Nucl Med Commun; 2005 Nov; 26(11):989-94. PubMed ID: 16208177
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oncologic 18F-FDG PET/CT: referring physicians' point of view.
    Karantanis D; Kalkanis D; Allen-Auerbach M; Bogsrud TV; Subramaniam RM; Danielson A; Lowe VJ; Czernin J
    J Nucl Med; 2012 Oct; 53(10):1499-505. PubMed ID: 22917886
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.